Cargando…

Effects of switching from prandial premixed insulin therapy to basal plus two times bolus insulin therapy on glycemic control and quality of life in patients with type 2 diabetes mellitus

BACKGROUND: The effects of switching from prandial premixed insulin therapy (PPT) injected three times a day to basal plus two times bolus insulin therapy (B2B) on glycemic control and quality of life were investigated in patients with type 2 diabetes mellitus. METHODS: The clinical course was prosp...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Hiroyuki, Abe, Mariko, Antoku, Shinichi, Omoto, Takashi, Shinozaki, Masahiro, Nishio, Shinya, Mifune, Mizuo, Togane, Michiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003145/
https://www.ncbi.nlm.nih.gov/pubmed/24790413
http://dx.doi.org/10.2147/DDDT.S62709
_version_ 1782313822935056384
author Ito, Hiroyuki
Abe, Mariko
Antoku, Shinichi
Omoto, Takashi
Shinozaki, Masahiro
Nishio, Shinya
Mifune, Mizuo
Togane, Michiko
author_facet Ito, Hiroyuki
Abe, Mariko
Antoku, Shinichi
Omoto, Takashi
Shinozaki, Masahiro
Nishio, Shinya
Mifune, Mizuo
Togane, Michiko
author_sort Ito, Hiroyuki
collection PubMed
description BACKGROUND: The effects of switching from prandial premixed insulin therapy (PPT) injected three times a day to basal plus two times bolus insulin therapy (B2B) on glycemic control and quality of life were investigated in patients with type 2 diabetes mellitus. METHODS: The clinical course was prospectively observed during the first 16 weeks after switching to B2B (insulin glargine plus insulin glulisine before breakfast and dinner) in 27 subjects previously treated with PPT using 50/50 premixed insulin. The Diabetes Treatment Satisfaction Questionnaire (DTSQ) was administered at the start and end of the study. RESULTS: The glycated hemoglobin (HbA(1c)) level (8.3%±1.8% to 8.2%±1.1%) and the DTSQ score did not change between the start and end of the study. An improvement in HbA(1c) level was found in nine (33%) subjects. The change in HbA(1c) showed a significant negative correlation with baseline HbA(1c), and was significantly better in patients with a baseline HbA(1c) >8.0% than in those with an HbA(1c) ≤8.0% (−0.9±2.0 versus 0.3±0.6, respectively, P=0.02). The change in DTSQ score representing treatment satisfaction was significantly greater in patients whose HbA(1c) level was improved than in those in whom it was not (2.7±3.6 versus −0.8±3.5, P=0.04). CONCLUSION: B2B was noninferior to PPT with regard to HbA(1c) levels in patients with type 2 diabetes mellitus. B2B should be considered particularly for subjects whose glycemic control is poor despite PPT.
format Online
Article
Text
id pubmed-4003145
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-40031452014-04-30 Effects of switching from prandial premixed insulin therapy to basal plus two times bolus insulin therapy on glycemic control and quality of life in patients with type 2 diabetes mellitus Ito, Hiroyuki Abe, Mariko Antoku, Shinichi Omoto, Takashi Shinozaki, Masahiro Nishio, Shinya Mifune, Mizuo Togane, Michiko Drug Des Devel Ther Original Research BACKGROUND: The effects of switching from prandial premixed insulin therapy (PPT) injected three times a day to basal plus two times bolus insulin therapy (B2B) on glycemic control and quality of life were investigated in patients with type 2 diabetes mellitus. METHODS: The clinical course was prospectively observed during the first 16 weeks after switching to B2B (insulin glargine plus insulin glulisine before breakfast and dinner) in 27 subjects previously treated with PPT using 50/50 premixed insulin. The Diabetes Treatment Satisfaction Questionnaire (DTSQ) was administered at the start and end of the study. RESULTS: The glycated hemoglobin (HbA(1c)) level (8.3%±1.8% to 8.2%±1.1%) and the DTSQ score did not change between the start and end of the study. An improvement in HbA(1c) level was found in nine (33%) subjects. The change in HbA(1c) showed a significant negative correlation with baseline HbA(1c), and was significantly better in patients with a baseline HbA(1c) >8.0% than in those with an HbA(1c) ≤8.0% (−0.9±2.0 versus 0.3±0.6, respectively, P=0.02). The change in DTSQ score representing treatment satisfaction was significantly greater in patients whose HbA(1c) level was improved than in those in whom it was not (2.7±3.6 versus −0.8±3.5, P=0.04). CONCLUSION: B2B was noninferior to PPT with regard to HbA(1c) levels in patients with type 2 diabetes mellitus. B2B should be considered particularly for subjects whose glycemic control is poor despite PPT. Dove Medical Press 2014-04-23 /pmc/articles/PMC4003145/ /pubmed/24790413 http://dx.doi.org/10.2147/DDDT.S62709 Text en © 2014 Ito et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Ito, Hiroyuki
Abe, Mariko
Antoku, Shinichi
Omoto, Takashi
Shinozaki, Masahiro
Nishio, Shinya
Mifune, Mizuo
Togane, Michiko
Effects of switching from prandial premixed insulin therapy to basal plus two times bolus insulin therapy on glycemic control and quality of life in patients with type 2 diabetes mellitus
title Effects of switching from prandial premixed insulin therapy to basal plus two times bolus insulin therapy on glycemic control and quality of life in patients with type 2 diabetes mellitus
title_full Effects of switching from prandial premixed insulin therapy to basal plus two times bolus insulin therapy on glycemic control and quality of life in patients with type 2 diabetes mellitus
title_fullStr Effects of switching from prandial premixed insulin therapy to basal plus two times bolus insulin therapy on glycemic control and quality of life in patients with type 2 diabetes mellitus
title_full_unstemmed Effects of switching from prandial premixed insulin therapy to basal plus two times bolus insulin therapy on glycemic control and quality of life in patients with type 2 diabetes mellitus
title_short Effects of switching from prandial premixed insulin therapy to basal plus two times bolus insulin therapy on glycemic control and quality of life in patients with type 2 diabetes mellitus
title_sort effects of switching from prandial premixed insulin therapy to basal plus two times bolus insulin therapy on glycemic control and quality of life in patients with type 2 diabetes mellitus
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003145/
https://www.ncbi.nlm.nih.gov/pubmed/24790413
http://dx.doi.org/10.2147/DDDT.S62709
work_keys_str_mv AT itohiroyuki effectsofswitchingfromprandialpremixedinsulintherapytobasalplustwotimesbolusinsulintherapyonglycemiccontrolandqualityoflifeinpatientswithtype2diabetesmellitus
AT abemariko effectsofswitchingfromprandialpremixedinsulintherapytobasalplustwotimesbolusinsulintherapyonglycemiccontrolandqualityoflifeinpatientswithtype2diabetesmellitus
AT antokushinichi effectsofswitchingfromprandialpremixedinsulintherapytobasalplustwotimesbolusinsulintherapyonglycemiccontrolandqualityoflifeinpatientswithtype2diabetesmellitus
AT omototakashi effectsofswitchingfromprandialpremixedinsulintherapytobasalplustwotimesbolusinsulintherapyonglycemiccontrolandqualityoflifeinpatientswithtype2diabetesmellitus
AT shinozakimasahiro effectsofswitchingfromprandialpremixedinsulintherapytobasalplustwotimesbolusinsulintherapyonglycemiccontrolandqualityoflifeinpatientswithtype2diabetesmellitus
AT nishioshinya effectsofswitchingfromprandialpremixedinsulintherapytobasalplustwotimesbolusinsulintherapyonglycemiccontrolandqualityoflifeinpatientswithtype2diabetesmellitus
AT mifunemizuo effectsofswitchingfromprandialpremixedinsulintherapytobasalplustwotimesbolusinsulintherapyonglycemiccontrolandqualityoflifeinpatientswithtype2diabetesmellitus
AT toganemichiko effectsofswitchingfromprandialpremixedinsulintherapytobasalplustwotimesbolusinsulintherapyonglycemiccontrolandqualityoflifeinpatientswithtype2diabetesmellitus